BCG(Bacillus Calmette-Guerin) for Superficial Transitional Cell Carcinoma of the Bladder: A Preliminary Report(I).
- Author:
Choal Hee PARK
1
;
Sung Won LEE
;
Youn Kyoo CHUNG
;
Chun Il KIM
;
Kwang Sae KIM
;
Sung Choon LEE
Author Information
1. Department of Urology, Keimyung University School of Medicine, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
BCG;
transitional cell carcinoma;
bladder
- MeSH:
Bacillus;
Carcinoma, Transitional Cell*;
Humans;
Mycobacterium bovis;
Urinary Bladder*
- From:Korean Journal of Urology
1986;27(5):663-668
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tice-Chicago strain bacillus Calmette-Guerin was used to treat superficial transitional cell carcinoma of the bladder in 11 patients. The treatment regimen of 120mg. Tice-Chicago strain bacillus Calmette-Guerin weekly for 6 weeks and then monthly for 3 months was well tolerated. Side effects during or shortly after treatment were minor and self-limiting in the majority of patients (fever, bladder irritability and hematuria). Although the findings are still preliminary, they appear to hold promise of a new therapeutic approach to the treatment of a group of carcinoma of the bladder for which effective therapy is still lacking in this country.
